Abstract | OBJECTIVE: METHODS: We immunohistochemically examined the expression of Glut1 in 60 surgically resected primary lesions and 95 metastatic LNs of ESCC and classified them into 3 groups. The FDG accumulation was assessed with a positron emission tomography (PET). RESULTS: In the primary tumors, a high Glut1 expression was found to be significantly associated with advanced lesions: depth of tumor (p < 0.01), LN metastasis (p < 0.05) and advanced pathological stage (p < 0.01). The Glut1 expression of the metastatic LNs significantly correlated with that of each primary tumor (p < 0.001). The PET-positive lesions had a larger size and higher Glut1 expression than the PET-negative lesions in both the primary tumors and metastatic LNs. CONCLUSIONS: In both the primary tumors and metastatic LNs of ESCC, the Glut1 expression and tumor size correlated with the FDG accumulation and influence the sensitivity of the PET scan.
|
Authors | Yukiharu Hiyoshi, Masayuki Watanabe, Yu Imamura, Youhei Nagai, Yoshifumi Baba, Naoya Yoshida, Eiichiro Toyama, Naoko Hayashi, Hideo Baba |
Journal | Oncology
(Oncology)
Vol. 76
Issue 4
Pg. 286-92
( 2009)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 19262068
(Publication Type: Journal Article)
|
Copyright | Copyright 2009 S. Karger AG, Basel. |
Chemical References |
- Glucose Transporter Type 1
- SLC2A1 protein, human
- Fluorodeoxyglucose F18
|
Topics |
- Adult
- Aged
- Carcinoma, Squamous Cell
(metabolism, pathology)
- Esophageal Neoplasms
(metabolism, pathology)
- Female
- Fluorodeoxyglucose F18
(pharmacokinetics)
- Glucose Transporter Type 1
(analysis)
- Humans
- Immunohistochemistry
- Lymphatic Metastasis
- Male
- Middle Aged
- Positron-Emission Tomography
|